PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-37.55%
Both yoy net incomes decline, with AGEN at -3.58%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
14.84%
D&A growth well above AGEN's 16.04%. Michael Burry would suspect heavier depreciation burdens that might erode net income unless top-line follows suit.
No Data
No Data available this quarter, please select a different quarter.
0.81%
Less SBC growth vs. AGEN's 10.15%, indicating lower equity issuance. David Dodd would confirm the firm still retains key staff.
106.29%
Slight usage while AGEN is negative at -0.46%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
81.80%
Some yoy usage while AGEN is negative at -243.02%. John Neff would see competitor possibly generating more free cash from minor accounts than we do.
No Data
No Data available this quarter, please select a different quarter.
9.51%
Operating cash flow growth below 50% of AGEN's 23.99%. Michael Burry would see a serious shortfall in day-to-day cash profitability.
38.16%
Some CapEx rise while AGEN is negative at -140.88%. John Neff would see competitor possibly building capacity while we hold back expansions.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
38.16%
Lower net investing outflow yoy vs. AGEN's 104.50%, preserving short-term cash. David Dodd would confirm expansions remain sufficient.
No Data
No Data available this quarter, please select a different quarter.
1171.17%
We slightly raise equity while AGEN is negative at -30.27%. John Neff sees competitor possibly preserving share count or buying back shares.
No Data
No Data available this quarter, please select a different quarter.